The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Coronary artery disease (acute) - Myocardial ischemia/infarction
Publications
Tomita Y, Sueta D, Kakiuchi Y, Saeki S, Saruwatari K, Sakata S, Jodai T, Migiyama Y, Akaike K, Hirosako S, Fujisue K, Yamamura S, Miyazaki S, Takashio S, Izumiya Y, Nakamura K, Tsujita K, Ichiyasu H, Fujii K
Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody.
Annals of oncology : official journal of the European Society for Medical Oncology 2017 11 01;28;2893-2895 — 2017 11 01 — 2893-2895